Press Releases Press Releases SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes May 19, 2022 Read More World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump April 26, 2022 Read More First Patient in Japan Treated with Impella 5.5® with SmartAssist® April 6, 2022 Read More Regulators Approve Impella 5.5® with SmartAssist® in Japan and Hong Kong; US FDA Grants Impella BTR® Conditional IDE Approval for First-in-Human Early Feasibility Study January 19, 2022 Read More Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology January 19, 2022 Read More Two Large Studies Demonstrate Complete Revascularization with Impella® Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes November 5, 2021 Read More Impella® Advances to Higher Level of Recommendation in Newest ESC Guidelines November 4, 2021 Read More TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology November 2, 2021 Read More FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump August 19, 2021 Read More FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure June 30, 2021 Read More Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients June 1, 2021 Read More Endergebnisse der NCSI (National Cardiogenic Shock Initiative) - Studie zeigen Vorteil einer frühzeitigen Herzentlastung mit Impella Herzpumpen April 30, 2021 Weiterlesen Abiomed beruft Dr. Paula A. Johnson in das Board of Directors April 29, 2021 Weiterlesen First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella® April 16, 2021 Read More Abiomed erhält Zulassung für Inbetriebnahme von erweiterter Reinraum- und Produktionsfläche am Standort Aachen March 30, 2021 Weiterlesen 1 2 3 4 NPS-2558
